Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03936465
Recruitment Status : Recruiting
First Posted : May 3, 2019
Last Update Posted : October 15, 2019
Sponsor:
Collaborator:
Stand Up To Cancer
Information provided by (Responsible Party):
Steven DuBois, Dana-Farber Cancer Institute

Tracking Information
First Submitted Date  ICMJE April 30, 2019
First Posted Date  ICMJE May 3, 2019
Last Update Posted Date October 15, 2019
Actual Study Start Date  ICMJE September 27, 2019
Estimated Primary Completion Date July 10, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 1, 2019)
  • Dose Limiting Toxicity Rate [ Time Frame: 28 days (first cycle) ]
    Dose limiting toxicity as defined in protocol
  • The Rate of Toxicities of BMS-986158 [ Time Frame: 2 years ]
    Adverse events coded using CTCAE version 5
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03936465 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 1, 2019)
  • Objective Response Rate [ Time Frame: 2 years ]
    Objective response rate
  • Pharmacokinetics of BMS-986158 [ Time Frame: 2 years ]
    Plasma concentrations of BMS-986158
  • Pharmacodynamics of BMS-986158 [ Time Frame: 2 years ]
    Gene expression levels in peripheral blood
  • Blood Markers of Response [ Time Frame: 2 years ]
    Levels of ctDNA in peripheral blood
  • CSF Markers of Response [ Time Frame: 2 years ]
    Levels of ctDNA in CSF
  • Tumor Markers of Response [ Time Frame: 2 years ]
    Levels of Myc proteins in tumor
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer
Official Title  ICMJE Phase 1 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer
Brief Summary This research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors, lymphoma, or brain tumors.
Detailed Description

This is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved BMS-986158 as a treatment for any disease.

BMS-986158 is currently still being studied in adults. This is the first time that BMS-986158 will be evaluated in younger children, though children 12-17 years of age may also be included in parts of adult studies of BMS-986158.

Research in the laboratory has shown that BMS-986158 may have activity against cancer cells. BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Solid Tumor, Childhood
  • Lymphoma
  • Brain Tumor, Pediatric
Intervention  ICMJE Drug: BMS-986158
BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
Study Arms  ICMJE
  • Experimental: Cohort A
    • Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
    • Patients with unselected relapsed or refractory solid tumors or lymphoma
    Intervention: Drug: BMS-986158
  • Experimental: Cohort B
    • Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
    • Patients with relapsed or refractory solid tumors, lymphoma, or CNS tumors that have defined molecular features predicted to increase sensitivity to BET inhibition
    Intervention: Drug: BMS-986158
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 1, 2019)
34
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 10, 2024
Estimated Primary Completion Date July 10, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≤ 21 years at time of enrollment. Note the requirement in section 3.1.6 that all patients must be able to swallow intact capsules.
  • Karnofsky performance status ≥ 50% for patients ≥16 years of age or Lansky ≥ 50% for patients <16 years of age (see Appendix A)
  • Diagnosis requirement

    • Participants must have evaluable or measurable disease (see Section 11).
    • Must have disease that is relapsed or refractory and for which standard curative measures do not exist or are no longer effective.
    • For Cohort A, participants must have histologically confirmed non-CNS primary solid tumors or lymphoma based upon biopsy or surgery at relapse/progression. Patients without biopsy or surgery at relapse/progression and with tissue only available from initial diagnosis may still be considered after discussion with the overall Primary Investigator.
    • For Cohort B, participants must have histologically confirmed solid tumors, lymphoma, or primary CNS tumor based upon biopsy or surgery at relapse/progression as well as documentation of one of the following confirmed tumor molecular features obtained in a laboratory certified to return results for clinical purposes. Patients without biopsy or surgery at relapse/progression and with tissue only available from initial diagnosis may still be considered after discussion with the overall Primary Investigator.
    • MYCN amplification or high copy number gain
    • MYC amplification or high copy number gain
    • Translocation involving MYC or MYCN
    • Translocation involving BRD4 or BRD3
  • Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy except organ function as noted in Section 3.1.5. Patients must meet the following minimum washout periods prior to enrollment:
  • Myelosuppressive chemotherapy: At least 14 days after the last dose of myelosuppressive chemotherapy (42 days for nitrosourea or mitomycin C).
  • Radiotherapy:

    • At least 14 days after local XRT (small port, including cranial radiation);
    • At least 90 days must have elapsed after prior TBI, craniospinal XRT or if >50% radiation of pelvis;
    • At least 42 days must have elapsed if other substantial BM radiation;
    • At least 42 days must have passed since last MIBG or other radionuclide therapy.
  • Small molecule biologic therapy: At least 7 days following the last dose of a small molecule biologic agent. For agents with known adverse events occurring beyond 7 days, this duration must be extended beyond the time in which adverse events are known to occur. If extended duration is required, this must be discussed with and approved by the overall PI.
  • Monoclonal antibody: At least 28 days must have elapsed after the last dose of therapeutic monoclonal antibody.
  • Myeloid growth factors: At least 14 days following the last dose of long-acting growth factor (e.g. Neulasta) or 7 days following short-acting growth factor.
  • Autologous hematopoietic stem cell transplant and stem cell boost: Patients must be at least 60 days from day 0 of an autologous stem cell transplant or autologous stem cell boost.
  • Cellular therapies (including CAR-T cells) and other non-cellular, non-antibody immunotherapies (e.g., vaccines): At least 42 days must have elapsed after last dose.
  • Major Surgery: At least 2 weeks from prior major surgical procedure. Note: Major surgical procedure will be considered all surgical procedures aside from the following: Biopsy; central line placement/removal; bone marrow aspirate/biopsy; lumbar puncture; dental procedures; gastrostomy tube placement; and VP shunt placement/revision.
  • BET inhibitors: Patients must not have received prior treatment with a BET inhibitor.
  • Participants must have normal organ function as defined below.
  • Bone Marrow Function
  • For Patients without Documented Bone Marrow Involvement by Disease:

    • Hemoglobin > 8 g/dL (may be transfused)
    • Absolute neutrophil count ≥ 1,000 /uL
    • Platelets ≥ 100,000 /uL and transfusion independent, defined as not receiving a platelet transfusion for at least 5 days prior to CBC documenting eligibility.
  • For Patients with Documented Bone Marrow Involvement by Disease:

    • Hemoglobin > 8 g/dL (may be transfused)
    • Absolute neutrophil count ≥ 750 /uL
    • Platelets ≥ 75,000 /uL and transfusion independent, defined as not receiving a platelet transfusion for at least 5 days prior to CBC documenting eligibility.
  • Hepatic Function:

    • Total bilirubin ≤ 1.5 x upper limit of normal for age (patients with known Gilbert's may be considered after discussion with overall PI and if direct bilirubin is at or below the upper limit of normal for age)
    • ALT (SGPT) ≤ 3 x upper limit of normal (135 U/L) For the purpose of this study, the ULN for ALT is 45 U/L
    • Serum albumin > 2 g/dL
  • Adequate Pancreatic Function:

    --Lipase < upper limit of normal

  • Adequate GI Function:

    --Diarrhea < grade 1 by CTCAE version 5

  • Coagulation Factors:

    • International Normalized Ratio (INR) < 1.5
    • Partial thromboplastin time (PTT) < 1.5 times upper limit of normal
  • For patients having labs drawn via heparinized catheters, it is important to request heparin-absorbed values.
  • Adequate Cardiac Function:

    --QTc < 480 msec

  • Renal Function:

    • A serum creatinine within protocol limits based on age/sex.

OR

  • Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels greater than the above age/sex maximum allowed values.
  • Able to swallow intact capsules.
  • Patient (or parent or legally authorized representative, if minor) is able to understand and willing to provide informed consent, using an institutionally approved informed consent procedure.
  • Participants of childbearing or child-fathering potential must agree to use adequate contraception throughout their participation following the guidance in Appendix H.

Exclusion Criteria:

  • Prior solid organ or allogeneic stem cell transplantation.
  • Patients with primary or metastatic CNS tumors, except:

    • Patients with primary CNS tumor meeting definition for Cohort B;
    • Patients with a history of CNS metastatic disease that has been resected and/or radiated without evidence of active CNS disease for 3 months preceding enrollment;
    • Patients with lymphoma and CSF involvement.
  • Patients receiving any of the following prohibited foods and medications:

    • Agents listed in Appendix B within 7 days prior to enrollment
    • Grapefruit or Seville oranges and/or their juices within 7 days prior to enrollment
    • Non-steroidal anti-inflammatory drugs, oral anticoagulants, and therapeutic heparins (unfractionated or low molecular weight heparin) at the time of enrollment. Note: Use of heparin to maintain patency of a central or peripheral catheter is allowed
    • Other investigational agents being administered under an IND.
  • Pregnant participants will not be entered on this study given that the effects of BMS-986158 on the developing human fetus are unknown. Female participants of childbearing potential must have a documented negative pregnancy exam within 24 hours prior to dosing.
  • Breastfeeding mothers are not eligible, because there is an unknown risk for adverse events in nursing infants secondary to treatment of the mother with BMS-986158.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BMS-986158.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients with a known history of HIV, hepatitis B, and/or hepatitis C (testing not required as part of screening).
  • Patients with gastrointestinal disease or disorder that could interfere with absorption of BMS-986158, such as bowel obstruction or inflammatory bowel disease.
  • Patients with a body surface area < 0.3 m2
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 1 Year to 21 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Steven G DuBois, MD,MS 617-632-5460 steven_dubois@dfci.harvard.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03936465
Other Study ID Numbers  ICMJE 19-040
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Steven DuBois, Dana-Farber Cancer Institute
Study Sponsor  ICMJE Dana-Farber Cancer Institute
Collaborators  ICMJE Stand Up To Cancer
Investigators  ICMJE
Principal Investigator: Steven G. DuBois, MD, MS Dana-Farber Cancer Institute
PRS Account Dana-Farber Cancer Institute
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP